Susquehanna International Group’s Bone Biologics BBLG Stock Holding History

Susquehanna International Group’s Portfolio BBLG Stock Details BBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-36	Closed	-$10.7K	–	12550
2022 Q4	$10.7K	Buy	+36	New	+$20.3K	﹤0.01%	11929

Other funds holding BBLG

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Susquehanna International Group's BBLG Position: Q1 2023 in Review

Susquehanna International Group sold out of Bone Biologics (BBLG) in Q1 2023, closing a stake of 36 shares — an estimated $10.7K sold.

Susquehanna International Group first reported a position in BBLG in Q4 2022 and held it in 1 quarter. The position peaked at $10.7K in Q4 2022. 7 funds tracked by Wall St. Rank hold BBLG as of Q1 2023.

Susquehanna International Group reported no remaining Bone Biologics position as of Q1 2023 after selling out during the quarter.
Susquehanna International Group sold 36 Bone Biologics shares in Q1 2023, an estimated $10.7K.
Susquehanna International Group first reported a position in Bone Biologics in Q4 2022 and held it in 1 quarter.
Susquehanna International Group's Bone Biologics position peaked at $10.7K in Q4 2022.
7 funds tracked by Wall St. Rank held Bone Biologics as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.